# Robert L. Coleman

Source: https://onco.cc/people/robert-coleman/  
OnCo record `robert-coleman` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer.

## Summary

Robert Coleman (US Oncology Research, Texas) was principal investigator of ARIEL3, which established rucaparib maintenance in recurrent ovarian cancer, and of GOG-0213, which found no survival benefit from secondary cytoreductive surgery but confirmed bevacizumab's benefit at relapse. He served as GOG programme director and has led many NRG gynaecological trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; parp; surgery
- Role: Chief Scientific Officer, US Oncology Research; Gynecologic Oncologist, Texas Oncology
- Specialisms: Ovarian cancer; PARP inhibitors; Antiangiogenic therapy; Surgical trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Coleman%20RL%5BAuthor%5D%20ovarian%20rucaparib

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [PARP](https://onco.cc/targets/parp/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- institutions: [The US Oncology Network / US Oncology Research](https://onco.cc/institutions/us-oncology-network/)

---
JSON: https://onco.cc/api/v1/entities/robert-coleman.json